Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmaceutical cost growth under capitation: a case study.

M Chernew1, M E Cowen, D M Kirking

  • 1Department of Health Management and Policy, University of Michigan (UM) School of Public Health, USA.

Health Affairs (Project Hope)
|February 24, 2001
PubMed
Summary

Drug spending growth under physician capitation initially lagged but eventually accelerated as physician risk decreased. This highlights challenges in controlling escalating pharmaceutical costs within healthcare systems.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of Novel Colorectal Neoplasia Screening Tests.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Stroke risk stratification in acute dizziness presentations: A prospective imaging-based study.

Neurology·2015
Same author

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.

Alimentary pharmacology & therapeutics·2011
Same author

Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.

Alimentary pharmacology & therapeutics·2008
Same author

As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.

Alimentary pharmacology & therapeutics·2008
Same author

The effect of extended grazing time and supplementary forage on the dry matter intake and foraging behaviour of cattle kept under traditional african grazing systems.

Tropical animal health and production·2007

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Healthcare Management

Background:

  • Rising pharmaceutical spending poses significant challenges for healthcare purchasers and policymakers.
  • Understanding drug cost growth dynamics is crucial, as interventions reducing cost levels may not impact growth rates.
  • Managed care systems vary in how they manage physician financial risk for drug expenditures.

Purpose of the Study:

  • To compare pharmaceutical cost growth between a capitated healthcare system and other managed care models.
  • To analyze the impact of physician financial risk on drug spending growth over time.
  • To identify factors influencing the acceleration of drug costs in capitated environments.

Main Methods:

  • Comparative analysis of drug cost growth data.

Related Experiment Videos

  • Examination of changes in capitation rates and physician risk transfer over time.
  • Focus on the rate of cost growth rather than the absolute cost level.

    • Main Results:

    • Drug cost growth under capitation was initially lower than in other systems but exceeded target rates.
    • Over time, capitation rates increased, and the financial risk transferred to physicians diminished.
    • These changes correlated with an acceleration in drug spending growth within the capitated system.

    Conclusions:

    • Capitation models may initially curb drug spending growth but are susceptible to acceleration.
    • Declining physician financial risk in capitated systems can lead to increased drug expenditure growth.
    • Policy interventions must consider the long-term dynamics of cost growth and physician incentives.